Direct oral anticoagulants (DOAC s) have quickly become attractive alternatives to the long‐
standing standard of care in anticoagulation, vitamin K antagonist. DOAC s are indicated for …

Given its complexity, the management of atrial fibrillation (AF) has relied increasingly on
expert guideline recommendations; however, discrepancies between these professional …

Abstract The Canadian Cardiovascular Society (CCS) atrial fibrillation (AF) guidelines
program was developed to aid clinicians in the management of these complex patients, as …

Background Patients on long-term dialysis are at increased risk of bleeding. Although oral
anticoagulants (OACs) are recommended for atrial fibrillation (AF) to reduce the risk of …

Patients with ischemic stroke or transient ischemic attack and non-valvular atrial fibrillation
have a high risk of recurrent stroke and other vascular events. The aim of this guideline is to …

Atrial fibrillation (AF) and venous thromboembolism (VTE) are highly prevalent conditions
with a significant healthcare burden, and represent the main indications for anticoagulation …

The consensus of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in
atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for …

Cardiovascular disease is an emerging medical issue in patients with hemophilia (PWH)
and its prevalence is increasing up to 15% in PWH in the United States. Atrial fibrillation …

Direct oral anticoagulants (DOACs) have been shown to be superior to vitamin K
antagonists (VKAs) in regards to safety and efficacy in numerous clinical trials and are now …

Apixaban in patients with impaired renal function is supported by limited data. Landmark
clinical trials evaluating apixaban in patients with atrial fibrillation and/or acute venous …